Please login to the form below

Not currently logged in
Email:
Password:

Merrimack Pharma

This page shows the latest Merrimack Pharma news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack

French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by second-line pancreatic cancer therapy Onivyde. ... The deal includes Onivyde (liposomal irinotecan) and Merrimack's generic version of Doxil (liposomal

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit ... The antibody was developed by Daiichi Sankyo's

  • Baxter and Merrimack file pancreatic cancer drug in EU Baxter and Merrimack file pancreatic cancer drug in EU

    Baxter and Merrimack Pharma have filed for approval of their pancreatic cancer therapy MM-398 in the EU, a few days after the FDA started a priority review of the drug. ... The FDA has already given the drug priority review status and Merrimack and Baxter

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics